Payment overview · 2025
General Payments
$461.02
26 reported records · 11 companies
Healthcare provider profile · identity verified
Megan Patrick, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GEORGETOWN, SC · NPI 1801419213
Verified facts
What the public records show
CMS Open Payments records show Megan Patrick, NP-C received $461.02 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.07 | 33.2% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.69 | 12.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.14 | 8.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.00 | 7.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.97 | 7.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.98 | 7.4% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $24.50 | 5.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.13 | 5.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.74 | 4.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.94 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.86 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $461.02 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.03 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.69 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $41.14 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.88 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $6.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 264 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 237 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 48 |
| Omeprazole | Omeprazole | 170 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 35 |
| Losartan Potassium | Losartan Potassium | 131 | 39 |
| Lisinopril | Lisinopril | 119 | 31 |
| Metformin Hcl | Metformin Hcl | 118 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 30 |
| Sertraline Hcl | Sertraline Hcl | 99 | 25 |
| Trazodone Hcl | Trazodone Hcl | 86 | 28 |
| Ozempic | Semaglutide | 78 | 13 |
| Potassium Chloride | Potassium Chloride | 78 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 20 |
| Simvastatin | Simvastatin | 63 | 15 |
| Chlorthalidone | Chlorthalidone | 62 | 20 |
| Carvedilol | Carvedilol | 60 | 16 |
| Gabapentin | Gabapentin | 59 | 26 |
| Valsartan | Valsartan | 59 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Furosemide | Furosemide | 55 | 21 |
| Montelukast Sodium | Montelukast Sodium | 55 | 14 |
| Famotidine | Famotidine | 54 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 15 |
| Allopurinol | Allopurinol | 52 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 50 | 49 |
| Meloxicam | Meloxicam | 50 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 13 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Glipizide | Glipizide | 35 | suppressed |
| Prednisone | Prednisone | 33 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 11 |
| Eliquis | Apixaban | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Naproxen | Naproxen | 24 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vimpat | Lacosamide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $461.02 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INJECTAFER, JARDIANCE, LEQVIO, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error